Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukine in melanoma
NCT02451488Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- May 2015
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sargramostim in melanoma, sponsored by Mayo Clinic. Primary endpoint: Th1/Th2 Normalized Gene Expression at 14 days. Started May 2015; status: completed.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02451488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451488.